Vir Biotechnology, Inc. (VIR) Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Vir Biotechnology, Inc. NASDAQ:VIR Healthcare · Biotechnology
Mkt Cap $1.91B
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors
Vir Biotechnology appointed Dr. Suzanne Topalian, a leading cancer immunotherapy researcher at Johns Hopkins, to its Board of Directors effective October 27, 2026.
Dr. Topalian's foundational work on PD-1 blockade helped establish immune checkpoint inhibition as a pillar of modern oncology, and she brings depth relevant to Vir's masked T-cell engager and PRO-XTEN oncology programs.
This is a routine governance update with no change to the company's strategy or financial outlook.
• 4d ago AI analysis › Press Release
Vir Biotechnology to Host Conference Call for Third Quarter 2026 Financial Results
Vir Biotechnology will host a conference call at 4:30 p.m. ET on Wednesday, November 4 to provide a corporate update and discuss Q3 2026 financial results.
The release contains no financial figures or new business developments -- it is solely a scheduling notice with access details via the company's investor relations site.
• 11d ago AI analysis › Press Release ● Major ⚠ 1
Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors
Vir Biotechnology announced a collaboration and license agreement with Gilead to discover and develop three novel PRO-XTEN dual-masked T-cell engagers for solid tumors, with Gilead taking an exclusive license to develop and commercialize the candidates.
Vir receives up to $135 million in upfront and near-term preclinical milestones, comprising $65 million cash, a $25 million equity investment at a 30% premium, and up to $45 million in milestones.
Beyond that, Vir is eligible for up to $1.74 billion in development, regulatory and commercial milestones plus tiered high single-digit to low double-digit royalties on net sales.
This is Vir's second collaboration built on the PRO-XTEN masking platform, which management cited as external validation of its discovery capabilities.
• 18d ago AI analysis › Press Release ⚠ 1
Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer
The FDA granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager, for the treatment of late-line metastatic castration-resistant prostate cancer.
VIR-5500 is being co-developed with Astellas Pharma under a global strategic collaboration and is currently in a Phase 1 trial across six dose-expansion cohorts, with earlier data showing promising anti-tumor activity and general tolerability.
Fast Track is intended to expedite development and review; pivotal Phase 3 trials are anticipated to begin in 2027.
• 24d ago AI analysis › Press Release
Vir Biotechnology Appoints David Liu as Chief Medical Officer
Vir Biotechnology appointed David Liu, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 12, 2026, overseeing clinical development, medical affairs and regulatory affairs.
Dr. Liu joins from Nuvation Bio, where he was CMO, with more than 25 years of oncology experience at 3D Medicines, Celgene, Bristol Myers Squibb and AstraZeneca.
The hire comes as Vir advances its Phase 3 chronic hepatitis delta program and a pipeline of masked T-cell engager cancer immunotherapies, strengthening regulatory-execution depth ahead of key milestones.
• 25d ago AI analysis › Press Release
Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026
Vir Biotechnology will present expanded Phase 2 SOLSTICE data for elebsiran and tobevibart in chronic hepatitis delta at AASLD's The Liver Meeting 2026 in Denver, November 5-9.
Two oral presentations are scheduled for November 8: one covering HDV RNA response patterns through Week 96 and another a translational sub-study on intrahepatic NK cell remodelling.
The release contains no new efficacy results; the actual data will be disclosed at the conference and could shape expectations for the hepatitis delta program.
• 27d ago AI analysis › Press Release
Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer
Vir Biotechnology appointed Aziz Sawaf as Executive Vice President and Chief Financial Officer, effective October 5, 2026, leading finance, IT and investor relations.
Sawaf was CFO of Theravance Biopharma since 2023 and brings more than 20 years of biopharma finance experience, including prior roles at Gilead Sciences.
The appointment arrives as Vir advances its hepatitis delta program and PRO-XTEN dual-masked T-cell engager oncology pipeline, with management citing disciplined capital allocation as a priority.
• 1mo ago AI analysis › Press Release
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Vir Biotechnology CEO Marianne De Backer will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City.
The presentation is scheduled for Monday, September 14 at 7:45 a.m. ET.
A live webcast will be accessible via the company's investor relations website and archived for 30 days.
• 2mo ago AI analysis › Press Release ● Major
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Vir reported Q2 revenue of $238.9 million and net income of $80.1 million, or $0.47 per share, driven primarily by the $240.0 million upfront payment from Astellas.
The company ended the quarter with $1.01 billion in cash, extending its operational runway into the second half of 2028.
Phase 2 SOLSTICE data showed 88% of participants achieved undetectable HDV RNA at Week 96 with the elebsiran and tobevibart regimen, with Phase 3 ECLIPSE 1 topline data expected in Q4 2026.
• 2mo ago AI analysis › Press Release ⚠ 2
Vir Biotechnology Announces Chief Financial Officer Transition
Vir Biotechnology announced that Chief Financial Officer Jason O’Byrne is leaving the company to pursue another opportunity, with his last day scheduled for August 3.
Brent Sabatini, Senior Vice President and Chief Accounting Officer, has been appointed Interim Principal Financial Officer effective immediately.
The company has initiated a comprehensive search to identify its next permanent Chief Financial Officer.
• 3mo ago AI analysis › Press Release
Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results
Vir Biotechnology announced it will host a conference call on August 5 to discuss its financial results for the second quarter ended June 30, 2026.
The company is a clinical-stage biopharmaceutical firm focused on immunotherapies for infectious diseases and cancer, with programs for chronic hepatitis delta and solid tumors.
Vir retains exclusive rights to the PRO-XTEN masking platform, which is a trademark of Amunix Pharmaceuticals, a Sanofi company.
• 3mo ago AI analysis › Press Release
Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors
Vir Biotechnology appointed Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026.
Mr. Coughlin brings extensive experience as a former CFO of Neurocrine Biosciences and currently serves on the boards of aTyr Pharma, ADC Therapeutics, and Travere Therapeutics.
CEO Marianne De Backer emphasized that his background in transitioning companies to fully integrated commercial enterprises will support the advancement of Vir's hepatitis delta and oncology pipeline.
• 4mo ago AI analysis › Press Release
Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026
Vir Biotechnology will present complete Week 96 data from its Phase 2 SOLSTICE trial for chronic hepatitis delta at the EASL Congress 2026 in Barcelona.
The oral presentation, selected as 'Best of EASL 2026,' covers the efficacy and safety of tobevibart alone or in combination with elebsiran.
A separate poster presentation will detail a Week 48 subgroup analysis on the impact of BMI on ALT normalization following viral control.
• 5mo ago AI analysis › Press Release ● Major
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results
Vir Biotechnology reported Q1 2026 financial results with a net loss of $0.85 per share and a cash position of $809.3 million, boosted by a recently closed $172.5 million public offering.
The company finalized its global collaboration with Astellas for VIR-5500, triggering $315 million in combined payments, and dosed the first patient in Phase 1 dose-expansion cohorts for metastatic prostate cancer.
In chronic hepatitis delta, updated Phase 2 data showed 88% of participants achieved undetectable HDV RNA at Week 96, with pivotal Phase 3 topline data expected in Q4 2026.
• 5mo ago AI analysis › Press Release
Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference
Vir Biotechnology announced that CEO Marianne De Backer will participate in a fireside chat at the Bank of America Securities 2026 Healthcare Conference on May 12.
The session will be webcast live on the company's website and archived for 30 days following the event.
The company describes itself as a clinical-stage biopharmaceutical firm focused on immunotherapies for infectious diseases and cancer.
• 5mo ago AI analysis › 
